Relevant concomitant care permitted or prohibited during the trial {11d}
peripheral neuropathy, nausea, vomiting
PERIPHERAL NEUROPATHY
If a patient develops peripheral neuropathy during the clinical trial, the study drug will be discontinued and such patients will receive treatment at the treating physician’s discretion. Supportive care drugs for nausea, vomiting, and other chemotherapy-associated side effects will be permitted in the study. Oral opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are allowed if needed.Oral tricyclic antidepressants, pregabalin, and duloxetine therapy will not be permitted, and patients who require these drugs will discontinue the study treatment after discussion with the principal investigator.